Merck’s MF/F Phase III study data presented at AAAAI annual meeting (News-Medical-Net)
March 3, 2010 — JesseData from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.
See original here:
Merck’s MF/F Phase III study data presented at AAAAI annual meeting (News-Medical-Net)